Aeon biopharma completes enrollment in phase 2 study of abp-450 (prabotulinumtoxina) for preventive treatment of chronic migraine

– expect to announce topline data in q3 2024 – – company plans in q1 2024 an end-of-phase 2 meeting with the fda to discuss the phase 3 program in episodic migraine – – anticipate shortening the open label extension (ole) study to 2 treatment cycles – irvine, calif., dec. 12, 2023 (globe newswire) -- aeon biopharma, inc. (“aeon” or the “company”) (nyse: aeon, aeon ws), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced today completion of enrollment with the last patient first visit in the phase 2 study of abp-450 for the preventive treatment of chronic migraine.
AEON Ratings Summary
AEON Quant Ranking